New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection.

IF 4.6 Q1 ONCOLOGY 癌症耐药(英文) Pub Date : 2023-08-17 eCollection Date: 2023-01-01 DOI:10.20517/cdr.2023.86
Michael M Gottesman, Robert W Robey, Suresh V Ambudkar
{"title":"New mechanisms of multidrug resistance: an introduction to the <i>Cancer Drug Resistance</i> special collection.","authors":"Michael M Gottesman, Robert W Robey, Suresh V Ambudkar","doi":"10.20517/cdr.2023.86","DOIUrl":null,"url":null,"abstract":"<p><p><i>Cancer Drug Resistance</i> publishes contributions to understanding the biology and consequences of mechanisms that interfere with successful treatment of cancer. Since virtually all patients who die of metastatic cancer have multidrug-resistant tumors, improved treatment will require an understanding of the mechanisms of resistance to design therapies that circumvent these mechanisms, exploit these mechanisms, or inactivate these multidrug resistance mechanisms. One example of a resistance mechanism is the expression of ATP-binding cassette efflux pumps, but unfortunately, inhibition of these transporters has not proved to be the solution to overcome multidrug resistance in cancer. Other mechanisms that confer multidrug resistance, and the confluence of multiple different mechanisms (multifactorial multidrug resistance) have been identified, and it is the goal of this Special Collection to expand this catalog of potential multidrug resistance mechanisms, to explore novel ways to overcome resistance, and to present thoughtful reviews on the problem of multidrug resistance in cancer.</p>","PeriodicalId":70759,"journal":{"name":"癌症耐药(英文)","volume":"6 3","pages":"590-595"},"PeriodicalIF":4.6000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571052/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"癌症耐药(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/cdr.2023.86","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer Drug Resistance publishes contributions to understanding the biology and consequences of mechanisms that interfere with successful treatment of cancer. Since virtually all patients who die of metastatic cancer have multidrug-resistant tumors, improved treatment will require an understanding of the mechanisms of resistance to design therapies that circumvent these mechanisms, exploit these mechanisms, or inactivate these multidrug resistance mechanisms. One example of a resistance mechanism is the expression of ATP-binding cassette efflux pumps, but unfortunately, inhibition of these transporters has not proved to be the solution to overcome multidrug resistance in cancer. Other mechanisms that confer multidrug resistance, and the confluence of multiple different mechanisms (multifactorial multidrug resistance) have been identified, and it is the goal of this Special Collection to expand this catalog of potential multidrug resistance mechanisms, to explore novel ways to overcome resistance, and to present thoughtful reviews on the problem of multidrug resistance in cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多药耐药性的新机制:癌症耐药性专集简介。
癌症耐药性发表了对理解干扰癌症成功治疗的机制的生物学和后果的贡献。由于几乎所有死于转移性癌症的患者都患有耐多药肿瘤,改善治疗需要了解耐药机制,以设计绕过这些机制、利用这些机制或灭活这些耐多药机制的疗法。耐药机制的一个例子是ATP结合盒外排泵的表达,但不幸的是,抑制这些转运蛋白并没有被证明是克服癌症多药耐药性的解决方案。已经确定了赋予多药耐药性的其他机制,以及多种不同机制的汇合(多因素多药耐药性),本专题集的目标是扩大潜在的多药耐药性机制目录,探索克服耐药性的新方法,并对癌症多药耐药问题进行了深入的综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.60
自引率
0.00%
发文量
0
期刊最新文献
Exploring resistance to immune checkpoint inhibitors and targeted therapies in melanoma. NFE2L2 and ferroptosis resistance in cancer therapy. The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models. Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies. Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1